Ziqian Peng
Newcastle Upon Tyne, ENG NE13BZ, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Siglec-15 is a glyco-immune checkpoint in prostate cancer regulating immune evasion and metastasis.
Journal: bioRxiv : the preprint server for biology
Published: August 20, 2026
Comprehensive profiling reveals Sialyl-Tn upregulation and prognostic value in prostate cancer.
Journal: bioRxiv : the preprint server for biology
Published: April 27, 2026
Comprehensive Profiling Reveals Sialyl-Tn Upregulation and Prognostic Value in Prostate Cancer.
Journal: Pathology international
Published: April 16, 2026
Blocking glycan production by targeting GALNT7 for prostate cancer therapy.
Journal: Expert opinion on therapeutic targets
Published: January 20, 2026
Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis.
Journal: British journal of cancer
Published: November 26, 2025
FUT8 Is a Critical Driver of Prostate Tumour Growth and Can Be Targeted Using Fucosylation Inhibitors.
Journal: Cancer medicine
Published: February 13, 2025
Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone.
Journal: EBioMedicine
Published: July 07, 2023
An expression signature at diagnosis to estimate prostate cancer patients' overall survival.
Journal: Prostate cancer and prostatic diseases
Published: August 28, 2013
Showing 1-10 of 10
Last Updated: 09/26/2026